These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 30614355)

  • 1. The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma.
    Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
    Acta Oncol; 2019 Mar; 58(3):379-381. PubMed ID: 30614355
    [No Abstract]   [Full Text] [Related]  

  • 2. Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
    Di Pietro FR; Marinelli D; Verkhovskaia S; Poti G; Falcone R; Carbone ML; Morelli MF; Zappalà AR; Di Rocco ZC; Morese R; Piesco G; Chesi P; Marchetti P; Failla CM; De Galitiis F
    BMC Cancer; 2024 Oct; 24(1):1220. PubMed ID: 39354418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
    Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
    Ann Oncol; 2017 Jul; 28(7):1672-1673. PubMed ID: 28407116
    [No Abstract]   [Full Text] [Related]  

  • 4. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
    Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
    Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M
    J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
    Huffman BM; Kottschade LA; Kamath PS; Markovic SN
    Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
    Chang W; Lee SJ; Park S; Choi MK; Hong JY; Kim YS; Maeng CH; Jung HA; Kim S; Lee J
    Melanoma Res; 2013 Apr; 23(2):147-51. PubMed ID: 23411477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of nivolumab in melanoma.
    Gomes F; Serra-Bellver P; Lorigan P
    Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
    Carlino MS; Long GV
    Clin Cancer Res; 2016 Aug; 22(16):3992-8. PubMed ID: 27340279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous graft-versus-host disease with combined immune checkpoint blockade.
    Kofler L; Dréno B; Röcken M
    Eur J Cancer; 2018 Sep; 101():275-277. PubMed ID: 30017386
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
    Govindan R; Szczesna A; Ahn MJ; Schneider CP; Gonzalez Mella PF; Barlesi F; Han B; Ganea DE; Von Pawel J; Vladimirov V; Fadeeva N; Lee KH; Kurata T; Zhang L; Tamura T; Postmus PE; Jassem J; O'Byrne K; Kopit J; Li M; Tschaika M; Reck M
    J Clin Oncol; 2017 Oct; 35(30):3449-3457. PubMed ID: 28854067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
    Meier F; Guenova E; Clasen S; Eigentler T; Forschner A; Leiter U; Zielinski C; Knaudt B; Garbe C; Berneburg M
    J Am Acad Dermatol; 2009 May; 60(5):863-8. PubMed ID: 19389529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.
    Guo YQ; Ding Y; Li DD; Li JJ; Peng RQ; Wen XZ; Zhang X; Zhang XS
    Med Oncol; 2015 Sep; 32(9):234. PubMed ID: 26298530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.